You are currently viewing Biocon Biologics appoints Deepali Naair as Global Head – Brand & Corporate Communications

Biocon Biologics appoints Deepali Naair as Global Head – Brand & Corporate Communications

Bengaluru: Biocon Biologics Limited, a fully integrated global
biosimilars company and a subsidiary of Biocon Limited, has announced the appointment of Deepali Naair as Global Head – Brand & Corporate Communications, effective immediately.

Deepali will lead the global brand and corporate communications function, responsible for defining
and executing an integrated strategy that spans brand positioning, digital presence, regulatory and
statutory communications, financial and corporate reporting, media relations, and employer
branding.

Deepali will join the Executive Leadership Team (ELT) and report directly to Shreehas Tambe, CEO &
Managing Director, Biocon Biologics Limited. 
She will be based at Biocon House, Bengaluru.

With over three decades of experience across India, ASEAN, and Australia, Deepali brings deep expertise in brand building, marketing, and corporate reputation. In her most recent role as Group Chief Marketing Officer at CKA Birla Group, she was instrumental in shaping the Group’s corporate identity, launching new brands, and driving strategic transformations. She also worked at IBM, IIFL Wealth Finance Ltd, IIFL Investment Managers, Mahindra Holidays & Resorts India Limited, L&T General Insurance Company Limited, HSBC Asset Management India Private Limited, EMM Group, Marico, FCB Ulka Advertising, BPL Mobile Communications Ltd, and Tata Motors.

Seema Ahuja, who was the Head of Communications for Emerging Markets and Corporate Brand, will
post her retirement from Biocon Biologics and move into a non-business facing role in Biocon
Chairperson’s office to work on special projects. 

Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited, said, “Branding and
communications play a pivotal role in shaping stakeholder perception, building trust, and translating
corporate intent into meaningful narratives. As Biocon Biologics accelerates its journey to become a
leading global biosimilars company, I am delighted to welcome Deepali and look forward to her
leadership and expertise in shaping our global brand and communications strategy.”

Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated, global biosimilars
company. Biocon Biologics has commercialized 10 biosimilars from its portfolio which are addressing the patients’ needs in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other noncommunicable diseases.

Leave a Reply